NCT02580708: Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer |
|
|
| Terminated | 1/2 | 7 | US | Rociletinib, CO-1686, Trametinib, Mekinist | Clovis Oncology, Inc., Novartis Pharmaceuticals | Non-small Cell Lung Cancer | 05/16 | 06/16 | | |